Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Common Equity (2016 - 2025)

Tg Therapeutics has reported Common Equity over the past 10 years, most recently at $648.0 million for Q4 2025.

  • Quarterly results put Common Equity at $648.0 million for Q4 2025, up 191.42% from a year ago — trailing twelve months through Dec 2025 was $648.0 million (up 191.42% YoY), and the annual figure for FY2025 was $648.0 million, up 191.42%.
  • Common Equity for Q4 2025 was $648.0 million at Tg Therapeutics, up from $607.2 million in the prior quarter.
  • Over the last five years, Common Equity for TGTX hit a ceiling of $648.0 million in Q4 2025 and a floor of $27.4 million in Q1 2023.
  • Median Common Equity over the past 5 years was $184.9 million (2024), compared with a mean of $237.5 million.
  • Biggest five-year swings in Common Equity: surged 33010.94% in 2021 and later plummeted 83.9% in 2023.
  • Tg Therapeutics' Common Equity stood at $237.2 million in 2021, then crashed by 75.3% to $58.6 million in 2022, then soared by 173.95% to $160.5 million in 2023, then soared by 38.54% to $222.4 million in 2024, then skyrocketed by 191.42% to $648.0 million in 2025.
  • The last three reported values for Common Equity were $648.0 million (Q4 2025), $607.2 million (Q3 2025), and $276.4 million (Q2 2025) per Business Quant data.